To date, suberoylanilide hydroxamic acid (SAHA), a second generation HDAC inhibitor, has shown to arrest cell cycle progression and promote cancer cell apoptosis in vitro on different solid tumours while its use in clinical trials is limited for the treatment of recurrent T-cell lymphoma.42 Here, HDAC9 is linked to cancer.